CA3128042A1 - Inhibiteurs specifiques du complexe ltbp de tgfs et leurs utilisations - Google Patents

Inhibiteurs specifiques du complexe ltbp de tgfs et leurs utilisations Download PDF

Info

Publication number
CA3128042A1
CA3128042A1 CA3128042A CA3128042A CA3128042A1 CA 3128042 A1 CA3128042 A1 CA 3128042A1 CA 3128042 A CA3128042 A CA 3128042A CA 3128042 A CA3128042 A CA 3128042A CA 3128042 A1 CA3128042 A1 CA 3128042A1
Authority
CA
Canada
Prior art keywords
seq
antibody
antigen
complex
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3128042A
Other languages
English (en)
Inventor
Thomas SCHURPF
Justin W. JACKSON
George CORICOR
Abhishek Datta
Stefan WAWERSIK
Christopher LITTLEFIELD
Adam FOGEL
Julia MCCREARY
Caitlin STEIN
Frederick STREICH Jr.
Matthew SALOTTO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scholar Rock Inc
Original Assignee
Coricor George
Fogel Adam
Jackson Justin W
Littlefield Christopher
Mccreary Julia
Salotto Matthew
Stein Caitlin
Streich Frederick Jr
Wawersik Stefan
Scholar Rock Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69423073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3128042(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Coricor George, Fogel Adam, Jackson Justin W, Littlefield Christopher, Mccreary Julia, Salotto Matthew, Stein Caitlin, Streich Frederick Jr, Wawersik Stefan, Scholar Rock Inc filed Critical Coricor George
Publication of CA3128042A1 publication Critical patent/CA3128042A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des inhibiteurs, tels que des anticorps et des fragments de liaison à l'antigène de ceux-ci qui se lient de manière sélective à des complexes de LTBP1-TGFß et/ou LTBP3-TGFß. L'invention concerne également des procédés d'utilisation de ces inhibiteurs pour, par exemple, inhiber l'activation de TGFß et traiter des sujets souffrant de troubles liés à TGFß tels que des affections fibrotiques. L'invention concerne également des procédés de sélection d'un inhibiteur de TGFß spécifique de l'isoforme dépendant ou indépendant du contexte pour un sujet en ayant besoin.
CA3128042A 2019-01-30 2020-01-30 Inhibiteurs specifiques du complexe ltbp de tgfs et leurs utilisations Pending CA3128042A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962798927P 2019-01-30 2019-01-30
US62/798,927 2019-01-30
PCT/US2020/015915 WO2020160291A2 (fr) 2019-01-30 2020-01-30 INHIBITEURS SPÉCIFIQUES DU COMPLEXE LTBP DE TGFβ ET LEURS UTILISATIONS

Publications (1)

Publication Number Publication Date
CA3128042A1 true CA3128042A1 (fr) 2020-08-06

Family

ID=69423073

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3128042A Pending CA3128042A1 (fr) 2019-01-30 2020-01-30 Inhibiteurs specifiques du complexe ltbp de tgfs et leurs utilisations

Country Status (21)

Country Link
US (4) US11214614B2 (fr)
EP (1) EP3689905A3 (fr)
JP (2) JP7724712B2 (fr)
KR (1) KR20210121174A (fr)
CN (1) CN113677711B (fr)
AR (1) AR117918A1 (fr)
AU (1) AU2020216177A1 (fr)
BR (1) BR112021015056A2 (fr)
CA (1) CA3128042A1 (fr)
CL (1) CL2021001993A1 (fr)
CO (1) CO2021010062A2 (fr)
CR (1) CR20210416A (fr)
DO (1) DOP2021000161A (fr)
EA (1) EA202192130A1 (fr)
IL (1) IL285076A (fr)
MA (1) MA54845A (fr)
MX (1) MX2021009175A (fr)
PE (1) PE20220279A1 (fr)
PH (1) PH12021551860A1 (fr)
SG (1) SG11202108099WA (fr)
WO (1) WO2020160291A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12358992B2 (en) 2017-07-28 2025-07-15 Scholar Rock, Inc. LTBP complex-specific inhibitors of TGF-beta 1 and uses thereof

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3350220T (lt) 2015-09-15 2021-09-27 Scholar Rock, Inc. Anti pro/latentinio miostatino antikūnai ir jų panaudojimas
AR117918A1 (es) 2019-01-30 2021-09-01 Scholar Rock Inc COMPLEJOS-ESPECÍFICOS LTBP INHIBIDORES DE TGFb Y SUS USOS
BR112022003412A2 (pt) 2019-08-28 2022-05-24 Chugai Pharmaceutical Co Ltd Anticorpos anti-tgf-beta 1 latente de espécies cruzadas e métodos de uso
US20230057012A1 (en) * 2020-01-11 2023-02-23 Scholar Rock, Inc. Tgfb inhibitors and use thereof
WO2022204581A2 (fr) 2021-03-26 2022-09-29 Scholar Rock, Inc. Inhibiteurs de tgf-bêta et leur utilisation
WO2022256723A2 (fr) 2021-06-03 2022-12-08 Scholar Rock, Inc. Inhibiteurs de tgf-bêta et leur utilisation thérapeutique
US20250319117A1 (en) * 2021-06-03 2025-10-16 The University Of Chicago Methods and compositions for treating fibrosis
MX2023014840A (es) * 2021-06-23 2024-02-12 Scholar Rock Inc Un inhibidor de la vía de la miostatina en combinación con un activador de la vía de la glp-1 para su uso en el tratamiento de trastornos metabólicos.
EP4370148A1 (fr) 2021-07-14 2024-05-22 Scholar Rock, Inc. Inhibiteurs spécifiques du complexe ltbp de tgf bêta1 et leurs utilisations
IL321628A (en) 2022-12-22 2025-08-01 Scholar Rock Inc Selective and potent inhibitory antibodies for myostatin activation
WO2024187051A1 (fr) 2023-03-07 2024-09-12 Scholar Rock, Inc. Inhibiteurs de tgf-bêta destinés à être utilisés pour traiter un cancer résistant ou réfractaire chez des patients
WO2025240343A1 (fr) 2024-05-13 2025-11-20 Scholar Rock, Inc. Inhibiteurs de tgf-bêta pour le traitement du cancer

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (fr) 1988-09-02 1997-04-02 Protein Engineering Corporation Production et selection de proteines de liaison diversifiees de recombinaison
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (fr) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methode de production de chainons de paires de liaison specifique
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
CA2405246A1 (fr) 1990-12-03 1992-06-11 Genentech, Inc. Methode d'enrichissement de proteines variantes aux proprietes liantes a lterees
EP0575485A1 (fr) 1991-03-01 1993-12-29 Dyax Corp. Procede de developpement de mini-proteines de liaison
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
US7138496B2 (en) 2002-02-08 2006-11-21 Genetastix Corporation Human monoclonal antibodies against human CXCR4
JP4653660B2 (ja) 2003-09-04 2011-03-16 独立行政法人理化学研究所 ＴＧＦ−β活性化制御領域の切断面を認識する抗体
WO2006086469A2 (fr) 2005-02-08 2006-08-17 Genzyme Corporation Anticorps anti-tgf-beta
ATE505489T1 (de) 2005-04-22 2011-04-15 Lilly Co Eli Tgf-beta-1-spezifische antikörper
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
WO2011102483A1 (fr) * 2010-02-19 2011-08-25 独立行政法人理化学研究所 ANTICORPS SE LIANT AU TGF-β DU LAP HUMAIN
SG195253A1 (en) * 2011-06-03 2013-12-30 Xoma Technology Ltd Antibodies specific for tgf-beta
US20150284455A1 (en) 2012-11-06 2015-10-08 Scholar Rock, Inc. Compositions and methods for modulating cell signaling
HRP20251426T1 (hr) * 2013-05-06 2026-01-02 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
EP3770171A1 (fr) 2015-04-03 2021-01-27 XOMA Technology Ltd. Traitement du cancer à l'aide d'inhibiteurs de tgf-bêta et pd-1
LT3350220T (lt) * 2015-09-15 2021-09-27 Scholar Rock, Inc. Anti pro/latentinio miostatino antikūnai ir jų panaudojimas
WO2017156500A1 (fr) * 2016-03-11 2017-09-14 Scholar Rock, Inc. Immunoglobulines se liant à tgfb1 et leur utilisation
AU2017283546C1 (en) 2016-06-13 2020-11-19 Scholar Rock, Inc. Use of myostatin inhibitors and combination therapies
US20190292254A1 (en) 2016-07-14 2019-09-26 Scholar Rock, Inc. TGFBeta Antibodies, Methods and Uses
US10375984B2 (en) 2016-07-18 2019-08-13 R.J. Reynolds Tobacco Company Nonwoven composite smokeless tobacco product
EP3497130B1 (fr) 2016-08-12 2021-10-27 Merck Patent GmbH Polythérapie contre le cancer
WO2018043734A1 (fr) * 2016-09-05 2018-03-08 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-tgf-beta 1 et leurs procédés d'utilisation
PE20191661A1 (es) * 2017-01-06 2019-11-11 Scholar Rock Inc Inhibidores de tgf beta1 isoforma-especificos contexto-permisivos y uso de los mismos
WO2018129331A1 (fr) 2017-01-07 2018-07-12 Merck Patent Gmbh Schémas posologiques et formes posologiques pour l'inhibition ciblée de tgf-b
EP3571227A1 (fr) 2017-01-20 2019-11-27 Sanofi Anticorps anti-tgf-bêta et leur utilisation
CN118255902A (zh) 2017-03-02 2024-06-28 加拿大国家研究委员会 TGF-β受体胞外域融合分子及其用途
US12358992B2 (en) * 2017-07-28 2025-07-15 Scholar Rock, Inc. LTBP complex-specific inhibitors of TGF-beta 1 and uses thereof
MX2021000347A (es) 2018-07-11 2021-04-19 Scholar Rock Inc Inhibidores de tgf?1 selectivos de isoforma, de alta afinidad y usos de los mismos.
TW202019957A (zh) 2018-07-11 2020-06-01 美商供石公司 TGFβ1抑制劑及其用途
AR117918A1 (es) 2019-01-30 2021-09-01 Scholar Rock Inc COMPLEJOS-ESPECÍFICOS LTBP INHIBIDORES DE TGFb Y SUS USOS

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12358992B2 (en) 2017-07-28 2025-07-15 Scholar Rock, Inc. LTBP complex-specific inhibitors of TGF-beta 1 and uses thereof

Also Published As

Publication number Publication date
MX2021009175A (es) 2021-09-14
AU2020216177A1 (en) 2021-09-23
US11365245B2 (en) 2022-06-21
JP2025172758A (ja) 2025-11-26
AR117918A1 (es) 2021-09-01
SG11202108099WA (en) 2021-08-30
WO2020160291A2 (fr) 2020-08-06
CL2021001993A1 (es) 2022-04-08
CO2021010062A2 (es) 2021-08-09
US12173059B2 (en) 2024-12-24
PE20220279A1 (es) 2022-02-25
US20210047396A1 (en) 2021-02-18
DOP2021000161A (es) 2021-09-15
KR20210121174A (ko) 2021-10-07
WO2020160291A9 (fr) 2020-10-15
MA54845A (fr) 2021-09-29
WO2020160291A3 (fr) 2020-09-10
JP2022524281A (ja) 2022-05-02
PH12021551860A1 (en) 2022-05-16
CN113677711A (zh) 2021-11-19
EA202192130A1 (ru) 2021-12-28
US11214614B2 (en) 2022-01-04
JP7724712B2 (ja) 2025-08-18
TW202043267A (zh) 2020-12-01
EP3689905A2 (fr) 2020-08-05
US20220064276A1 (en) 2022-03-03
BR112021015056A2 (pt) 2022-01-11
CN113677711B (zh) 2025-05-30
IL285076A (en) 2021-09-30
EP3689905A3 (fr) 2021-02-24
US20250179164A1 (en) 2025-06-05
US20220363741A1 (en) 2022-11-17
CR20210416A (es) 2021-09-14

Similar Documents

Publication Publication Date Title
US12173059B2 (en) LTBP complex-specific inhibitors of TGFβ and uses thereof
US20240016928A1 (en) Isoform-specific, context-permissive tgfb1 inhibitors and use thereof
US12358992B2 (en) LTBP complex-specific inhibitors of TGF-beta 1 and uses thereof
US20250257125A1 (en) HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOF
US12122823B2 (en) Isoform-selective TGFB1 inhibitors and use thereof
US20210340238A1 (en) TGFß1 INHIBITORS AND USE THEREOF
JP7719779B2 (ja) ＴＧＦβ阻害剤およびその使用
JP2016179979A (ja) Ｐｃｓｋ９アンタゴニスト
RS66913B1 (sr) Anti-pro/latentna antitela miostatina i njihova upotreba
US20240301073A1 (en) LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb1 AND USES THEREOF
HK40033668A (en) Ltbp complex-specific inhibitors of tgf-beta and uses thereof
EA050469B1 (ru) СПЕЦИФИЧНЫЕ К LTBP-КОМПЛЕКСУ ИНГИБИТОРЫ TGFβ И ИХ ПРИМЕНЕНИЕ
HK40060054A (en) LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF
HK40060054B (zh) TGFβ的LTBP复合特异性抑制剂及其用途
WO2017174017A1 (fr) Protéine de liaison de la proprotéine convertase subtilisine kexine de type 9 et son application

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220825

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241015

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250123

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250123

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250123

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250214

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250218

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250630

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250630

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251203

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251203